Spinal implant developer Intrinsic Therapeutics has pulled in $18 million of a $20 million mixed offering of equity, options, and warrants, according to a filing with the SEC. Existing Intrinsic investors New Enterprise Associates, Spray Venture Partners, and New Leaf Venture Partners are listed as directors on the filing. The Woburn, MA-based company, which produces a prosthetic to treat disc herniation, closed a $21 million Series D round in summer 2007.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
